Clinical Scorecard: Pharma Supply Chains in the Crossfire
At a Glance
| Category | Detail |
|---|---|
| Condition | Pharmaceutical Supply Chain Disruption |
| Key Mechanisms | Impact of US Supreme Court ruling on tariffs and geopolitical tensions affecting costs and logistics. |
| Target Population | Pharmaceutical companies and their supply chain stakeholders. |
| Care Setting | Global pharmaceutical logistics and compliance environments. |
Key Highlights
- US Supreme Court ruling limits executive power to impose tariffs under IEEPA.
- Existing tariffs under Section 122 and Section 301 remain in effect, complicating compliance.
- Rising geopolitical tensions are increasing costs and delaying clinical trials.
- Companies are reassessing supply chains and securing key ingredients.
- Proactive procurement and strategic positioning of products are essential.
Guideline-Based Recommendations
Diagnosis
- Identify impacted products and applicable tariffs.
Management
- Review business continuity plans and drug supply networks.
Monitoring & Follow-up
- Conduct granular audits of HTS codes and tariff applications.
Risks
- Anticipate cost increases and supply shortages due to geopolitical events.
Patient & Prescribing Data
Patients relying on pharmaceutical therapies affected by supply chain disruptions.
Continued access to critical therapies may be jeopardized by logistical challenges.
Clinical Best Practices
- Engage customs brokers for tariff refund processes.
- Explore exemptions or special treatments to mitigate costs.
- Utilize bonded warehouses for strategic product storage.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
